Business Description
Glaukos Corp
NAICS : 339112
SIC : 3845
ISIN : US3773221029
Description
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.67 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -1.62 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 16.73 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.7 | |||||
| 3-Year EBITDA Growth Rate | 3.4 | |||||
| 3-Year FCF Growth Rate | -33.8 | |||||
| 3-Year Book Growth Rate | -13.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 49.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 23.75 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.24 | |||||
| 9-Day RSI | 43.77 | |||||
| 14-Day RSI | 47.12 | |||||
| 3-1 Month Momentum % | 12.73 | |||||
| 6-1 Month Momentum % | 25.44 | |||||
| 12-1 Month Momentum % | 122.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.54 | |||||
| Quick Ratio | 4.71 | |||||
| Cash Ratio | 3.66 | |||||
| Days Inventory | 215.08 | |||||
| Days Sales Outstanding | 47.27 | |||||
| Days Payable | 51.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | 1.5 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.61 | |||||
| Operating Margin % | -32.22 | |||||
| Net Margin % | -41.51 | |||||
| FCF Margin % | -22.55 | |||||
| ROE % | -27.46 | |||||
| ROA % | -16.02 | |||||
| ROIC % | -19.38 | |||||
| 3-Year ROIIC % | -41.56 | |||||
| ROC (Joel Greenblatt) % | -63.54 | |||||
| ROCE % | -15.85 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 19.33 | |||||
| PB Ratio | 11.24 | |||||
| Price-to-Tangible-Book | 22.57 | |||||
| EV-to-EBIT | -54.23 | |||||
| EV-to-Forward-EBIT | -111.92 | |||||
| EV-to-EBITDA | -76.43 | |||||
| EV-to-Forward-EBITDA | -137.42 | |||||
| EV-to-Revenue | 20.58 | |||||
| EV-to-Forward-Revenue | 15.43 | |||||
| EV-to-FCF | -91.23 | |||||
| Price-to-GF-Value | 2.12 | |||||
| Price-to-Projected-FCF | 52.53 | |||||
| Price-to-Net-Current-Asset-Value | 56.48 | |||||
| Price-to-Net-Cash | 1786.13 | |||||
| Earnings Yield (Greenblatt) % | -1.84 | |||||
| FCF Yield % | -1.08 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:GKOS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Glaukos Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 360.347 | ||
| EPS (TTM) ($) | -2.96 | ||
| Beta | 0.6 | ||
| 3-Year Sharpe Ratio | 1.15 | ||
| 3-Year Sortino Ratio | 2.22 | ||
| Volatility % | 28.93 | ||
| 14-Day RSI | 47.12 | ||
| 14-Day ATR ($) | 4.857652 | ||
| 20-Day SMA ($) | 140.2905 | ||
| 12-1 Month Momentum % | 122.77 | ||
| 52-Week Range ($) | 59.575 - 146.86 | ||
| Shares Outstanding (Mil) | 55.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Glaukos Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Glaukos Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Glaukos Corp Frequently Asked Questions
What is Glaukos Corp(GKOS)'s stock price today?
The current price of GKOS is $142.89. The 52 week high of GKOS is $146.86 and 52 week low is $59.58.
When is next earnings date of Glaukos Corp(GKOS)?
The next earnings date of Glaukos Corp(GKOS) is 2025-02-21 Est..
Does Glaukos Corp(GKOS) pay dividends? If so, how much?
Glaukos Corp(GKOS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers